title: Hepatitis B virus core-preS2 particles expressed by recombinant vaccinia virus.
abstract: Vaccinia virus (VV) recombinants expressing hepatitis B virus (HBV) surface (HBsAg) or core (HBcAg) antigens (Kunke et al., Virology 195, 132 - 139 (1993)] have been shown to raise specific antibodies in mice, nevertheless the levels of antibodies reactive with the preS2 and S antigens were low. In an attempt to enhance the immunogenicity of HBsAg-preS2, a fused C-preS2 gene was constructed. The fusion protein was expressed in E. coli and displayed both HBcAg and preS2 antigen as demonstrated by enzyme-linked immunosorbent assay (ELISA). The same gene was then expressed using recombinant VV and chimerical particles whose size and density were similar to those of native HBV core particles produced in CV-1 cells infected with recombinant VV. Unlike HBcAg, preS2 antigen could not be detected on these particles by ELISA but was revealed by immunoblot analysis only. The immunogenicity of the recombinant VV was evaluated in mice. Antibodies to HBcAg and VV antigen but not to preS2 antigen were found in sera of animals inoculated with 10(7) PFU of the recombinant VV. Presumably, HBcAg-preS2 particles produced in E. coli and in eukaryotic cells have a different conformation, and the presence of preS2 antigen on the surface of chimerical particle might be necessary for a pronounced antibody response.
authors.affiliation: Department of Experimental Virology, Institute of Haematology and Blood Transfusion, Prague, Czech Republic.
authors.forename: S
authors.initials: S
authors.lastname: Nemecková
authors.forename: V
authors.initials: V
authors.lastname: Sroller
authors.forename: D
authors.initials: D
authors.lastname: Kunke
authors.forename: J
authors.initials: J
authors.lastname: Krystofová
authors.forename: L
authors.initials: L
authors.lastname: Kutinová
mesh_terms: D000818:Animals; D002460:Cell Line; D002522:Chlorocebus aethiops; D004797:Enzyme-Linked Immunosorbent Assay; D004926:Escherichia coli; D005822:Genetic Vectors; D006511:Hepatitis B Antigens / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D006512:Hepatitis B Core Antigens / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D015151:Immunoblotting; D007125:Immunogenetics; D051379:Mice; D008813:Mice, Inbred ICR; D011498:Protein Precursors / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D051381:Rats; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology*; D014616:Vaccinia virus
chemical_list: D006511:Hepatitis B Antigens; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D011498:Protein Precursors; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic; C050807:presurface protein 2, hepatitis B surface antigen